Skip to main content

8 November 2025

Last updated: Saturday 8 November 2025

User account anon menu

Login
Register and subscribe

Search

Home
News
About MedNous
Research Directory
Contact Us
- Contact Form

Menu

Breadcrumb

Home
Research Directory

Research Directory

JAK2 inhibitors: a breakthrough in oncology?

Thursday 23 September 2010

Interviewee/Contributor

Jürg Eckhardt

Organisation

Bellevue Asset Management

Organisations

Noxxon Pharma AG
vasopharm GmbH
Sen-Jam Pharmaceutical
Edison Investment Research Ltd
SFL Regulatory Affairs & Scientific Communication GmbH
BerGenBio ASA
BioAlliance
Arecor Therapeutics Plc
Horizon Discovery Group Plc
Howrey LLP

Interviewees and Contributers

Ted Bianco
Thomas Lönngren
Carlton Brown
Sander Slootweg and Juliette Audet
Genghis Lloyd-Harris
Aleksandra Grasso
Paola Pozzi
Ceri Wiggins and Jon Moore
Richard Francis
Michael E. Hunt

Select a News Category

Clinical Research
Company News
Finance, Grants, Deals
IPR & Legal
Regenerative Medicine
Regulation & Policy
Research & University News

Recent Appointments

Werner Lanthaler appointed CEO of FairJourney Biologics

Thursday 6 November 2025

New CEO at Evaxion

Thursday 6 November 2025

Draig Therapeutics appoints President and CEO

Thursday 6 November 2025

Forbion appoints partner in growth fund

Thursday 6 November 2025

Amphista Therapeutics names executives to drive clinical development

Thursday 6 November 2025

View more appointments

Looking for more?

MedNous covers medical news and more. See more in our various site sections.

News
Industry appointments
Events
Research directory
Subscribe

Footer

Privacy policy

© 2025 Evernow Publishing Ltd.

Home
News
- News
- Appointments
- Events
About MedNous
Research Directory
Contact Us
- Contact Form